Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Change in Account Payables (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Change in Account Payables data on record, last reported at $1.4 million in Q4 2022.

  • For Q4 2022, Change in Account Payables rose 108.12% year-over-year to $1.4 million; the TTM value through Dec 2022 reached -$2.0 million, down 119.27%, while the annual FY2025 figure was $8.5 million, 4019.9% up from the prior year.
  • Change in Account Payables reached $1.4 million in Q4 2022 per AVIR's latest filing, up from -$12.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $12.7 million in Q2 2021 and bottomed at -$17.7 million in Q4 2021.
  • Average Change in Account Payables over 3 years is $651500.0, with a median of $1.2 million recorded in 2020.
  • The widest YoY moves for Change in Account Payables: up 2588.0% in 2021, down 322.7% in 2021.
  • A 3-year view of Change in Account Payables shows it stood at -$4.2 million in 2020, then tumbled by 322.7% to -$17.7 million in 2021, then surged by 108.12% to $1.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.4 million in Q4 2022, -$12.8 million in Q3 2022, and $10.2 million in Q2 2022.